tbuckley/cabot-search huggingface dataset:
Trajectory clusters of radiographic progression in patients with rheumatoid arthritis: associations with clinical variables
Authors: Alexander Platzer, Farideh Alasti, Josef S Smolen, Daniel Aletaha, Helga Radner, Stephan Blüml
Journal: Annals of the Rheumatic Diseases (2021)

Identification of trajectories of radiographic damage in rheumatoid arthritis (RA) by clustering patients according to the shape of their curve of Sharp-van der Heijde scores (SHSs) over time. Developing models to predict their progression cluster from baseline characteristics.Patient-level data over a 2-year period from five large randomised controlled trials on tumour necrosis factor inhibitors in RA were used. SHSs were clustered in a shape-respecting manner to identify distinct clusters of radiographic progression. Characteristics of patients within different progression clusters were compared at baseline and over time. Logistic regression models were developed to predict trajectory of radiographic progression using information at baseline.In total, 1887 patients with 7738 X-rays were used for cluster analyses. We identified four distinct clusters with characteristic shapes of radiographic progression: one with a stable SHS over the whole 2-year period (C0/lowChange; 86%); one with relentless progression (C1/rise; 5.8%); one with decreasing SHS (C2/improvement; 6.9%); one going up and down (C3/bothWays; 1.4%) of the SHS. Robustness of clusters were confirmed using different clustering methods. Regression models identified disease duration, baseline C-reactive protein (CRP) and SHS and treatment status as predictors for cluster assignment.We were able to identify and partly characterise four different clusters of radiographic progression over time in patients with RA, most remarkably one with relentless progression and another one with amelioration of joint damage over time, suggesting the existence of distinct patterns of joint damage accrual in RA.
Long-term Prognosis of Dilated Cardiomyopathy without Complete Left Ventricular Reverse Remodeling after Beta-blocker Therapy
Authors: Hoshikawa Eri, Matsumura Yoshihisa, Ookawa Makoto, Hayato Kayo, Hamagawa Kosuke, Kubo Toru, Yamasaki Naohito, Kitaoka Hiroaki, Yabe Toshikazu, Takata Jun, Nishinaga Masanori, Doi Yoshinori
Journal: Circulation (2007)
Integrative metabolomic characterisation identifies altered portal vein serum metabolome contributing to human hepatocellular carcinoma
Authors: Jinkai Liu, Wei Geng, Hanyong Sun, Changan Liu, Fan Huang, Jie Cao, Lei Xia, Hongchuan Zhao, Jianning Zhai, Qing Li, Xiang Zhang, Ming Kuang, Shunli Shen, Qiang Xia, Vincent Wai-Sun Wong, Jun Yu
Journal: Gut (2021)

Altered metabolites are important for the tumourigenicity of hepatocellular carcinoma (HCC). We performed integrative metabolomics analysis of the metabolites changes in portal venous blood and in comparison with the metabolites changes in liver tissues and stool samples of HCC patients and healthy liver donors.Serum (portal and central vein), liver tissue (HCC tumour and adjacent non-tumour, normal liver) and stool samples were collected from 102 subjects (52 HCC patients and 50 healthy controls) in the discovery cohort; and 100 subjects (50 HCC patients and 50 healthy controls) in an independent validation cohort. Untargeted metabolomic profiling was performed using high-performance liquid chromatography-mass spectrometry. The function of candidate metabolites was validated in hepatocyte cell lines.Detailed metabolomic evaluation showed distinct clusters of metabolites in serum, liver tissue and stool samples from patients with HCC and control individuals (p<0.001). HCC patients had significantly higher levels of portal vein serum and HCC tissue metabolites of DL-3-phenyllactic acid, L-tryptophan, glycocholic acid and 1-methylnicotinamide than healthy controls, which were associated with impaired liver function and poor survival. On the other hand, HCC patients had lower levels of linoleic acid and phenol in portal vein and stool samples than healthy controls. Linoleic acid and phenol significantly inhibited HCC proliferation, inferring their anti-HCC function as protective metabolites.The integrative metabolome analysis of serum, tissue and stool metabolites revealed unreported metabolic alterations in HCC patients. In portal vein, we identified elevated and depleted metabolites signifying that they might play a role in HCC development.
COVID-19 pneumonia and ROX index: Time to set a new threshold for patients admitted outside the ICU. Authors' reply
Authors: M.L. Vega, R. Dongilli, G. Olaizola, N. Colaianni, M.C. Sayat, L. Pisani, M. Romagnoli, G. Spoladore, I. Prediletto, G. Montiel, S. Nava
Journal: Pulmonology (2021)

COVID-19 pneumonia and ROX index: Time to set a new threshold for patients admitted outside the ICU.Authors' replyWe thank Dr. Garnier and Dr Blez for their careful reading of our study 1 and their useful comments 2 We agree with them that we may have misinterpreted their setting of High Flow Nasal Cannula (HFNC), and we apologize for the misunderstanding.It makes obviously sense that the flow was delivered at 60 L/min. 3 Concerning the point of respiratory rate, we think that it is a matter of wording.We believe our statement "ROX H12 had a greater predictive value than respiratory rate alone, in contrast with Blez et al." is true, because in their article, the authors reported an AUROC of RR of 0.81, that is superior to 0.78 (AUROC of ROX).It is a matter of mathematics, despite not being statistically significant.On the other hand, we are a bit concerned about the title of their manuscript "....better look at the respiratory rate".We strongly believe that "two is better than one" in particular in patients with COVID-19 infections.The pathophysiology of Acute Respiratory Failure during this pandemic is complex and not fully understood.Everyone dealing with these patients has noticed that the respiratory frequency and tidal volume may be affected differently in specific subgroups of patients.Increases in tidal volume are presumably due to higher recruitment of respiratory premotor neurons, whereas changes in frequency may be related to the network activity of the neurons located in the pre-Botzinger complex.In addition, COVID-19 patients with similar oxygenation efficiency may have markedly different compliance.This makes the combination of respiratory pattern and respiratory mechanics complex and multifactorial.Not surprisingly, a consistent group of patients may show the so-called "non-dyspnogenic acute hypoxia" while others, for the same level of PaO 2 , show an important distress.Obviously respiratory pattern may influence the PaO2/FiO2 ratio, 4 but SaO 2 is also determined by the efficiency of the a-c membrane.So to make a long story short, it is not only a matter of "less is more".Indeed, Drs Garnier and Blez argued that the ROX H12 "is a time point too late to really impact management in case of failure".The median time of HFNC failure, however, has been reported to vary but it is on average >24 h. 5-7Thus, this may suggest that a ROXH12 may give the clinician a better overview of the patient's outcomes, than a more praecox measurement.
Editor's Note: Functional Roles of <i>Src</i> and <i>Fgr</i> in Ovarian Carcinoma
Authors: Hye-Sun Kim, Hee Dong Han, Guillermo N. Armaiz-Pena, Rebecca L. Stone, Eun Ji Nam, Jeong-Won Lee, Mian M.K. Shahzad, Alpa M. Nick, Sun Joo Lee, Ju-Won Roh, Masato Nishimura, Lingegowda S. Mangala, Justin Bottsford-Miller, Gary E. Gallick, Gabriel Lopez-Berestein, Anil K. Sood
Journal: Clinical Cancer Research (2021)

The editors are publishing this note to alert readers to a concern about [this article][1] ([1][2]): in Fig. 5B, one of the representative Ki67 images was duplicated between the "Control siRNA/CH-NP" and "Src siRNA/CH-NP" groups. MD Anderson's Office of Research Oversight and Integrity
Abstract 17770: Utility of Plasma B-Type Natriuretic Peptide Levels for Cardiovascular Risk Assessment in Subjects with Albuminuria
Authors: Toshie Segawa, Fumitaka Tanaka, Shinji Makita, Toshiyuki Onoda, Masaki Ohsawa, Kozo Tanno, Kazuyoshi Itai, Kiyomi Sakata, Motoyuki Nakamura
Journal: Circulation (2011)

Background: The subjects with albuminuria is a high risk group for cardiovascular disease (CVD). Also, increased plasma B-type natriuretic peptide (BNP) levels have been reported to be associated with CVD risk in several clinical and population-based settings. However, it remains unknown whether CVD risk in subjects with albuminuria could be stratified by plasma BNP levels. METHODS: At baseline, we measured spot urinary albumin/creatinine concentrations (UACR) and plasma BNP concentration in the general population (n = 15,344). Albuminuria was defined by UACR more than 30 mg/g creatinine (Cr). Data from 3,214 subjects aged 40 to 80 (mean age = 65 years) with no cardiovascular history were analyzed. The cohort was divided into quartiles according to plasma BNP, and the CVD event free rate within each BNP quartile was estimated using the Kaplan-Meier method. In addition, Cox regression analysis was performed to examine the relative risk of onset of CVD events among the quartiles. RESULTS: The mean follow-up duration was 5.7 years. Cases admitted for CVD events (heart failure, stroke, myocardial infarction) in the cohort were surveyed prospectively. The event free rate of the highest BNP quartile showed the lowest event free ratio (p &lt; 0.001). After adjustment for established CVD risk factors including glycosylated hemoglobin (HbA1c) values and estimated glomerular filtration rate (eGFR), the hazard ratio (HR) for CVD events increased significantly according to BNP quartile (p for trend &lt; 0.001), and the HR for the highest BNP quartile was significantly elevated compared to that for the lowest quartile (HR = 2.43, 95% CI; 1.44 - 4.09: Figure). When subjects with diabetes or reduced eGFR (&lt;60) were excluded, the association remained to be robust (Figure). CONCLUSION: Elevated plasma BNP levels are a useful biomarker for CVD risk stratification in subjects with albuminuria independent of classical risk factors including diabetes or renal dysfunction.
In high-risk adults aged 50 to 80 y, USPSTF recommends annual lung cancer screening with LDCT (moderate certainty)
Authors: Lionel S. Lim
Journal: Annals of Internal Medicine (2021)

ACP Journal ClubAugust 2021In high-risk adults aged 50 to 80 y, USPSTF recommends annual lung cancer screening with LDCT (moderate certainty)Lionel S. Lim, MBBS, MPHLionel S. Lim, MBBS, MPHVA Bedford Healthcare System, Bedford, Massachusetts, USA (L.S.L.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJ202108170-086 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationUS Preventive Services Task Force; Krist AH, Davidson KW, et al. Screening for lung cancer: US Preventive Services Task Force recommendation statement. JAMA. 2021;325:962-70. https://pubmed.ncbi.nlm.nih.gov/33687470Clinical Impact RatingsGIM/FP/GP: Pulmonology: References1 National Cancer Institute: Surveillance, Epidemiology, and End Results Program. Cancer stat facts: lung and bronchus cancer. Accessed at https://seer.cancer.gov/statfacts/html/lungb.html on 22 May 2021. Google Scholar2 Meza R, Jeon J, Toumazis I, et al. Evaluation of the benefits and harms of lung cancer screening with low-dose computed tomography: modeling study for the US Preventive Services Task Force. JAMA. 2021;325:988-97. [PMID: 33687469] Google Scholar Author, Article, and Disclosure InformationAffiliations: VA Bedford Healthcare System, Bedford, Massachusetts, USA (L.S.L.)Disclosures: The commentator has reported no disclosures of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M20-7319.This article was published at Annals.org on 3 August 2021. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byLessons From Implementation of the U.S. Preventive Services Task Force Recommendations for Lung Cancer ScreeningKarina W. Davidson, PhD, MASc August 2021Volume 174, Issue 8Page: JC86KeywordsCancer screeningComputed axial tomographyDisclosureLung and intrathoracic tumorsLung cancer screeningLungsMortalityNumber needed to screenRisk ratioSystematic reviews ePublished: 3 August 2021 Issue Published: August 2021 Copyright & PermissionsCopyright © 2021 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Anticoagulation therapy promotes the tumor immune-microenvironment and potentiates the efficacy of immunotherapy by alleviating hypoxia
Authors: Jeong Uk Choi, Na Kyeong Lee, Hyungseok Seo, Seung Woo Chung, Taslim A Al-Hilal, Seong Jin Park, Seho Kweon, Nuri Min, Sang Kyoon Kim, Seohyun Ahn, Uk-Il Kim, Jin Woo Park, Chang-Yuil Kang, In-San Kim, Sang Yoon Kim, Kyungjin Kim, Youngro Byun
Journal: Journal for ImmunoTherapy of Cancer (2021)

Here, this study verifies that cancer-associated thrombosis (CAT) accelerates hypoxia, which is detrimental to the tumor immune microenvironment by limiting tumor perfusion. Therefore, we designed an oral anticoagulant therapy to improve the immunosuppressive tumor microenvironment and potentiate the efficacy of immunotherapy by alleviating tumor hypoxia. A novel oral anticoagulant (STP3725) was developed to consistently prevent CAT formation. Tumor perfusion and hypoxia were analyzed with or without treating STP3725 in wild-type and P selectin knockout mice. Immunosuppressive cytokines and cells were analyzed to evaluate the alteration of the tumor microenvironment. Effector lymphocyte infiltration in tumor tissue was assessed by congenic CD45.1 mouse lymphocyte transfer model with or without anticoagulant therapy. Finally, various tumor models including K-Ras mutant spontaneous cancer model were employed to validate the role of the anticoagulation therapy in enhancing the efficacy of immunotherapy. CAT was demonstrated to be one of the perfusion barriers, which fosters immunosuppressive microenvironment by accelerating tumor hypoxia. Consistent treatment of oral anticoagulation therapy was proved to promote tumor immunity by alleviating hypoxia. Furthermore, this resulted in decrease of both hypoxia-related immunosuppressive cytokines and myeloid-derived suppressor cells while improving the spatial distribution of effector lymphocytes and their activity. The anticancer efficacy of αPD-1 antibody was potentiated by co-treatment with STP3725, also confirmed in various tumor models including the K-Ras mutant mouse model, which is highly thrombotic. Collectively, these findings establish a rationale for a new and translational combination strategy of oral anticoagulation therapy with immunotherapy, especially for treating highly thrombotic cancers. The combination therapy of anticoagulants with immunotherapies can lead to substantial improvements of current approaches in the clinic.
Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies
Authors: F. Pommeret, J. Colomba, C. Bigenwald, A. Laparra, S. Bockel, A. Bayle, J.-M. Michot, T. Hueso, L. Albiges, P. Tiberghien, S. Marot, A. Jary, K. Lacombe, F. Barlesi, F. Griscelli, E. Colomba
Journal: Annals of Oncology (2021)
P-87 Real-world data of nivolumab in advanced hepatocellular carcinoma: A multi-centric and retrospective study
Authors: M. Sardinha, D. Simão, A. Reis, A. Spencer, A. Parmanande, R. Saraiva, F. Calinas, F. Filipe, P. Winckler, R. da Luz, M. Martins, J. Gramaça, M. Ramos, E. Cadavez, M. Moura, L. Gil, J. Presa, P. Carrola, I. Pinho, S. Carvalho
Journal: Annals of Oncology (2021)
エストロゲン受容体αは,サイクリンD1/MYCプロモーターにおいてプロゲステロン受容体と相互作用することにより,プロゲスチン誘発乳房腫瘍増殖を媒介する
Authors: Giulianelli Sebastian, P Vaque Jose, Soldati Rocio, Wargon Victoria, I Vanzulli Silvia, Martins Ruben, Zeitlin Eduardo, A Molinolo Alfredo, A Helguero Luisa, A Lamb Caroline, Gutkind J. Silvio, Lanari Claudia
Journal: Cancer Research (2012)
Covid-19: WHO calls for booster shot ban until end of September
Authors: Luke Taylor
Journal: BMJ (2021)

The World Health Organization has called for a moratorium on covid-19 booster shots until the end of September to help vaccines reach poorer nations facing shortages.Wealthier countries with widespread vaccine coverage should prioritise sending doses to those facing shortages before they start to administer extra doses to their own population, senior WHO officials said on 4 August. 1 "These populations need vaccines urgently, especially health workers, older people, and other vulnerable groups," WHO director general, Tedros Adhanom Ghebreyesus, told reporters."And yet even while hundreds of millions of people are still waiting for their first dose, some rich countries are moving towards booster doses."White House.WHO moratorium on covid booster shots is a "false choice."2021.www.youtube.com/watch?v=PesIcrNe7N4.
In-depth quantitative profiling of post-translational modifications of Timothy grass pollen allergome in relation to environmental pollution and oxidative stress
Authors: Katarina Smiljanić, Ivana Prodić, Danijela Apostolović, Anka Cvetković, Đorđe Veljković, Jelena Mutić, Marianne van Hage, Lidija M. Burazer, Tanja Ćirković-Veličković
Journal: Allergy (2019)
Dach1 Extends Artery Networks and Protects Against Cardiac Injury
Authors: Brian Raftrey, Ian M. Williams, Pamela E. Rios Coronado, Xiaochen Fan, Andrew H. Chang, Mingming Zhao, Robert Roth, Emily Trimm, Raquel Racelis, Gaetano D’Amato, Ragini Phansalkar, Alana Nguyen, Timothy Chai, Karen M. Gonzalez, Yue Zhang, Lay Teng Ang, Kyle M. Loh, Daniel Bernstein, Kristy Red-Horse
Journal: Circulation Research (2021)

[Figure: see text].
Exploration of Immune-Related Gene Expression in Osteosarcoma and Association With Outcomes
Authors: Wangmi Liu, Xiankuan Xie, Yiying Qi, Jiayan Wu
Journal: JAMA Network Open (2021)

<h3>Importance</h3> Host immune dysregulation is associated with initiation and development of osteosarcoma. In addition, immunotherapy for osteosarcomas requires some knowledge of the immune state of patients. <h3>Objective</h3> To perform an immunogenomic landscape analysis based on The Cancer Genome Atlas (TCGA) project, which provides osteosarcoma samples with clinical information. <h3>Design, Setting, and Participants</h3> This genetic association study was conducted from July 20, 2020, to September 20, 2020, as a secondary analysis of public data. Cox regression and risk score analyses were used to construct signatures of immune-related genes (IRGs) in 84 patients with osteosarcoma from TCGA with corresponding clinical information. Patients were divided into high- and low-risk groups with 42 individuals in each group according to their risk scores. Data were analyzed from July 20 to September 20, 2020. <h3>Main Outcomes and Measures</h3> Differentially expressed genes (DEGs) were analyzed between groups, and potential molecular mechanisms, expression regulation, and immune cell infiltration were also explored using bioinformation methods. A prognostic model based on independent risk factors selected from multivariate Cox hazard ratio regression was established to estimate 1-year overall survival. <h3>Results</h3> In this genetic association study based on 84 samples from patients with osteosarcoma from TCGA (mean [SD] age, 15.0 [4.8] years; 47 [56.0%] men; mean [SD] follow-up time, 4.1 [2.8] years), a total of 14 survival-associated IRGs were identified. Patients assigned to the high-risk group had worse survival than patients from the low-risk group (1 death [2.4%] vs 26 deaths [61.9%%];<i>P</i> &lt; .001). The protein digestion and absorption pathway was one of the associated pathways in the functional enrichment analysis (gene ratio, 2:8;<i>P</i> &lt; .001). The prognostic model based on metastases at diagnosis and risk score performed well in 1-year overall survival estimations (area under the curve, 0.947; 95% CI, 0.832-0.972). The risk score was correlated with immune cell infiltration (B cells:<i>r</i> = 0.331;<i>P</i> = .002; macrophages:<i>r</i> = 0.410;<i>P</i> &lt; .001; CD8 T cells:<i>r</i> = 0.230;<i>P</i> = .04). <h3>Conclusions and Relevance</h3> This genetic association study developed a prognostic modeling tool for osteosarcoma based on IRG expression profiles, which could result in improved survival rates through more individualized therapies. Further research on IRG expression profiles could provide potential targets for future studies on immune treatment for osteosarcoma.
Stem Cell Factor SOX2 Confers Ferroptosis Resistance in Lung Cancer via Upregulation of SLC7A11
Authors: Xinbo Wang, Yueqing Chen, Xudong Wang, Hongling Tian, Yanjin Wang, Jiali Jin, Zezhi Shan, Yu'e Liu, Zhenyu Cai, Xinyuan Tong, Yi Luan, Xiao Tan, Bing Luan, Xin Ge, Hongbin Ji, Xuejun Jiang, Ping Wang
Journal: Cancer Research (2021)

Abstract Ferroptosis is a lipid peroxidation-dependent cell death caused by metabolic dysfunction. Ferroptosis-associated enzymes are promising therapeutic targets for cancer treatment. However, such therapeutic strategies show limited efficacy due to drug resistance and other largely unknown underlying mechanisms. Here we report that cystine transporter SLC7A11 is upregulated in lung cancer stem-like cells (CSLC) and can be activated by stem cell transcriptional factor SOX2. Mutation of SOX2 binding site in SLC7A11 promoter reduced SLC7A11 expression and increased sensitivity to ferroptosis in cancer cells. Oxidation at Cys265 of SOX2 inhibited its activity and decreased the self-renewal capacity of CSLCs. Moreover, tumors with high SOX2 expression were more resistant to ferroptosis, and SLC7A11 expression was positively correlated with SOX2 in both mouse and human lung cancer tissue. Together, our study provides a mechanism by which cancer cells evade ferroptosis and suggests that oxidation of SOX2 can be a potential therapeutic target for cancer treatment. Significance: This study uncovers a SOX2–SLC7A11 regulatory axis that confers resistance to ferroptosis in lung cancer stem-like cells.
P-4 Prognostic and therapeutic values of tumor-infiltrating lymphocytes in localized colon cancer
Authors: S. Ben Nasr, A. Kallala, I. Ben Abdallah, A. Zribi, S. Alibi, M. Balti, S. Fendri, I. Msekni, S. Bizid, A. Haddauoi
Journal: Annals of Oncology (2021)
Gene Expression Profiling Is a Strong Predictor of Clinical Outcomes in Newly Diagnosed Multiple Myeloma
Authors: Catherine M. Claussen, Tammy Chuang, Maria Chaudhry, Hans C. Lee, Krina K. Patel, Qaiser Bashir, Simrit Parmar, Sairah Ahmed, Rohtesh S. Mehta, Sheeba K. Thomas, Tiffany A Richards, Yago Nieto, Elizabeth J Shpall, Muzaffar H. Qazilbash, Behrang Amini, Richard E Davis, Sattva S. Neelapu, Donna M. Weber, Robert Z. Orlowski, Lei Feng, Elisabet E. Manasanch
Journal: Blood (2017)